Huons Global Reports Q2 Revenue of 169.7 Billion KRW, Up 18% YoY

[Asia Economy Reporter Lee Gwan-joo] Huons Group recorded its highest-ever performance in the second quarter, driven by balanced sales growth across its business sectors.

Huons Global, the holding company of Huons Group, announced on the 16th that its consolidated sales for the second quarter reached 169.7 billion KRW, and operating profit was 20.4 billion KRW, representing increases of 18% and 5%, respectively, compared to the same period last year.

The second-quarter results were supported by steady growth from key subsidiaries such as Huons and Humedics. Huons achieved results in its contract manufacturing and beauty & well-being businesses, while Humedics saw growth across all business sectors, including aesthetics.

Huons’ consolidated sales amounted to 124.1 billion KRW, a 12% increase year-over-year. Sales from the contract manufacturing business, represented by pharmaceuticals and ophthalmic solutions, grew 39% year-over-year to 19.2 billion KRW. The beauty & well-being business segment grew 10% year-over-year, reaching 45.5 billion KRW. Notably, the health functional food Menolacto, a probiotic for menopause, recorded second-quarter sales of 10.8 billion KRW, surpassing 10 billion KRW in quarterly sales as a single brand.

Humedics also achieved sales of 31.7 billion KRW and operating profit of 7.6 billion KRW, marking growth of 45% and 179%, respectively, compared to the previous year. Hu M&C posted sales of 13.6 billion KRW and operating profit of 800 million KRW, turning profitable. Since acquiring Hubena in April and completing the merger in July, the company has expanded its healthcare total consumables business, resulting in increased sales and improved profitability.

Additionally, Huons Meditech contributed with sales of 16.2 billion KRW and operating profit of 1.8 billion KRW, while Huons Biopharma recorded sales of 8.5 billion KRW and operating profit of 1.9 billion KRW.

Huons Group restructured its business by merging existing companies to strengthen competitiveness across business areas. Hu M&C, Huons Foodience, and Huons Meditech aim to secure future strategic business growth momentum by reorganizing operations, enhancing expertise, and achieving economies of scale.

Song Soo-young, CEO of Huons Global, stated, “Huons Group will continuously expand its portfolio based on its core pharmaceutical business to achieve the goal of 1 trillion KRW in sales by 2025, evolving into a total healthcare group encompassing health functional foods, medical devices, and healthcare consumables.”